# EDGAR Filing Document

**Accession Number:** 0002133244
**File Stem:** 0000805928-26-000065
**Filing Date:** 2026-5
**Character Count:** 7233
**Document Hash:** e9a0d9fbe05acf4dfbf12b39ee1025e7
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000805928-26-000065.hdr.sgml**: 20260508

**ACCESSION NUMBER**: 0000805928-26-000065

**CONFORMED SUBMISSION TYPE**: 3

**PUBLIC DOCUMENT COUNT**: 1

**CONFORMED PERIOD OF REPORT**: 20260501

**FILED AS OF DATE**: 20260508

**DATE AS OF CHANGE**: 20260508

**REPORTING-OWNER**: 

**OWNER DATA:**
- **COMPANY CONFORMED NAME:** Quackenbush Doris
- **CENTRAL INDEX KEY:** 0002133244

**ORGANIZATION NAME:**

**FILING VALUES:**
- **FORM TYPE:** 3
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-36046
- **FILM NUMBER:** 26958190

**MAIL ADDRESS:**
- **STREET 1:** 9101 NORMANDY DRIVE
- **CITY:** MOUNT LAUREL
- **STATE:** NJ
- **ZIP:** 08054
**ISSUER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Axogen, Inc.
- **CENTRAL INDEX KEY:** 0000805928
- **STANDARD INDUSTRIAL CLASSIFICATION:** ELECTROMEDICAL & ELECTROTHERAPEUTIC APPARATUS [3845]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 411301878
- **STATE OF INCORPORATION:** MN
- **FISCAL YEAR END:** 1231

**BUSINESS ADDRESS:**
- **STREET 1:** 13631 PROGRESS BLVD.
- **STREET 2:** SUITE 400
- **CITY:** ALACHUA
- **STATE:** FL
- **ZIP:** 32615
- **BUSINESS PHONE:** (386) 462-6817

**MAIL ADDRESS:**
- **STREET 1:** 13631 PROGRESS BLVD.
- **STREET 2:** SUITE 400
- **CITY:** ALACHUA
- **STATE:** FL
- **ZIP:** 32615

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** AxoGen, Inc.
- **DATE OF NAME CHANGE:** 20111004

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** LECTEC CORP /MN/
- **DATE OF NAME CHANGE:** 19920703

### UNITED STATES SECURITIES AND EXCHANGE COMMISSION
**Washington, D.C. 20549**

## FORM 3

### INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

---

| | | |
|:---|:---|:---|
| **1. Name and Address of Reporting Person**<sup>*</sup><br>Quackenbush Doris<br><sub>(Last) (First) (Middle)</sub><br>13631 PROGRESS BLVD.,<br>SUITE 400<br><sub>(Street)</sub><br>ALACHUA, FL 32615<br><sub>(City) (State) (Zip)</sub> | **3. Issuer Name and Ticker or Trading Symbol**<br>Axogen, Inc. [ AXGN ] | **5. If Amendment, Date of Original Filed (Month/Day/Year)**<br>  |
| **2. Date of Event Requiring Statement (Month/Day/Year)**<br>2026-05-01 | **4. Relationship of Reporting Person(s) to Issuer**<br>(Check all applicable)<br>[ ] Director   [ ] 10% Owner<br>[X] Officer (give title below)   [ ] Other (specify below)<br>_Sales VP_ | **6. Individual or Joint/Group Filing (Check Applicable Line)**<br>[X] Form filed by One Reporting Person<br>[ ] Form filed by More than One Reporting Person |

---

## Table I - Non-Derivative Securities Beneficially Owned

---

|  |  |  |  |
| --- | --- | --- | --- |
| 1. Title of Security | 2. Amount of Securities Beneficially Owned | 3. Ownership Form | 4. Nature of Indirect Beneficial Ownership |
| Common Stock | 96294 | D |  |

---

## Table II - Derivative Securities Beneficially Owned

---

|  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 1. Title of Derivative Security | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | 3. Title and Amount of Underlying Securities | 3. Title and Amount of Underlying Securities | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| 1. Title of Derivative Security | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | 4. Conversion or Exercise Price | 5. Ownership Form | 6. Nature of Indirect Beneficial Ownership |
| Restricted Stock Units | <sup>(1)</sup> | <sup>(1)</sup> | Common Stock | 23000 | <sup>(2)</sup> | D |  |
| Employee Stock Option (right to purchase) | <sup>(3)</sup> | 2033-03-16 | Common Stock | 12375 | $8.27 | D |  |
| Restricted Stock Units | <sup>(4)</sup> | <sup>(4)</sup> | Common Stock | 38000 | <sup>(2)</sup> | D |  |
| Employee Stock Option (right to purchase) | <sup>(5)</sup> | 2032-03-16 | Common Stock | 5345 | $8.20 | D |  |
| Restricted Stock Units | <sup>(6)</sup> | <sup>(6)</sup> | Common Stock | 4750 | <sup>(2)</sup> | D |  |
| Employee Stock Option (right to purchase) | <sup>(7)</sup> | 2032-02-01 | Common Stock | 10285 | $8.60 | D |  |
| Employee Stock Option (right to purchase) | <sup>(8)</sup> | 2030-03-02 | Common Stock | 15542 | $11.88 | D |  |

---

### Footnotes:

(1) All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on February 26, 2030 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on February 26, 2028 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

(2) Each restricted stock unit represents a contingent right to receive one share of Axogen, Inc. common stock.

(3) All shares of Axogen, Inc. common stock underlying the employee stock option will be fully vested on March 16, 2027 (4 years from the option grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2025 (24 months from the option grant date) and an additional 12.5% of the aggregate shares vested or will vest each 6 months thereafter.

(4) All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 25, 2029 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vest on March 25, 2027 (24 months from the grant date) and an additional 25% of the aggregate shares vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

(5) All underlying options from this grant became fully vested on March 16, 2026.

(6) All shares of Axogen Inc. common stock underlying the restricted stock units will be fully vested on March 16, 2027 (4 years from the grant date) based upon a vesting schedule whereby 50% of the aggregate shares vested on March 16, 2025 (24 months from the grant date) and an additional 25% of the aggregate shares vested or will vest each 12 months thereafter. Vested shares will be delivered to the reporting person upon the vesting date.

(7) All underlying options from this grant became fully vested on February 1, 2026.

(8) All underlying options from this grant became fully vested on March 2, 2024.

**Signature:** /s/ Marc Began, as attorney-in-fact for Doris Quackenbush  
**Date:** 2026-05-08

### Remarks:

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**